Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 818945, 12 pages
http://dx.doi.org/10.1155/2009/818945
Review Article

Cross-Talk between PPAR and Insulin Signaling and Modulation of Insulin Sensitivity

Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari School of Medicine, Piazza Giulio Cesare, 11, 70124 Bari, Italy

Received 8 August 2009; Revised 30 October 2009; Accepted 2 December 2009

Academic Editor: Antonio Brunetti

Copyright © 2009 Anna Leonardini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARγ2: tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994. View at Google Scholar · View at Scopus
  2. J. Berger, H. V. Patel, J. Woods et al., “A PPAR? mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus,” Molecular and Cellular Endocrinology, vol. 162, no. 1-2, pp. 57–67, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-?,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Yang, C. Rachez, and L. P. Freedman, “Discrete roles for peroxisome proliferator-activated receptor γ and retinoid X receptor in recruiting nuclear receptor coactivators,” Molecular and Cellular Biology, vol. 20, no. 21, pp. 8008–8017, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. M. K. Hansen and T. M. Connolly, “Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis,” Current Opinion in Investigational Drugs, vol. 9, no. 3, pp. 247–255, 2008. View at Google Scholar · View at Scopus
  6. B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. N. Billin, “PPAR-β/δ agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home,” Expert Opinion on Investigational Drugs, vol. 17, no. 10, pp. 1465–1471, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Zieleniak, M. Wójcik, and L. A. Woźniak, “Structure and physiological functions of the human peroxisome proliferator-activated receptor γ,” Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 5, pp. 331–345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and ?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Krey, O. Braissant, F. L'Horset et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Google Scholar · View at Scopus
  13. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Google Scholar · View at Scopus
  14. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Zhang, D. L. Baker, S. Yasuda et al., “Lysophosphatidic acid induces neointima formation through PPAR? activation,” Journal of Experimental Medicine, vol. 199, no. 6, pp. 763–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor ? ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Lehmann, J. M. Lenhard, B. B. Oliver, G. M. Ringold, and S. A. Kliewer, “Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3406–3410, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. R. F. Kletzien, S. D. Clarke, and R. G. Ulrich, “Enhancement of adipocyte differentiation by an insulin-sensitizing agent,” Molecular Pharmacology, vol. 41, no. 2, pp. 393–398, 1992. View at Google Scholar · View at Scopus
  19. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure—activity relationship between peroxisome proliferator-activated receptor ? agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Google Scholar · View at Scopus
  20. A. Reifel-Miller, K. Otto, E. Hawkins et al., “A peroxisome proliferator-activated receptor a/? dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia,” Molecular Endocrinology, vol. 19, no. 6, pp. 1593–1605, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. I.-L. Lu, C.-F. Huang, Y.-H. Peng et al., “Structure-based drug design of a novel family of PPAR? partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities,” Journal of Medicinal Chemistry, vol. 49, no. 9, pp. 2703–2712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13919–13924, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. A. D. Adams, Z. Hu, D. von Langen et al., “O-arylmandelic acids as highly selective human PPAR a/? agonists,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 19, pp. 3185–3190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Chakrabarti, R. K. Vikramadithyan, P. Misra et al., “Ragaglitazar: a novel PPARa & PPAR? agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models,” British Journal of Pharmacology, vol. 140, no. 3, pp. 527–537, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Wolf, “The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis,” Nutrition Reviews, vol. 61, no. 11, pp. 387–390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-B. Kim, T. P. Ciaraldi, A. Kong et al., “Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110ß protein levels in skeletal muscle of type 2 diabetic subjects,” Diabetes, vol. 51, no. 2, pp. 443–448, 2002. View at Google Scholar · View at Scopus
  27. M. Beeson, M. P. Sajan, M. Dizon et al., “Activation of protein kinase C-? by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise,” Diabetes, vol. 52, no. 8, pp. 1926–1934, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. H. K. R. Karlsson, K. Hällsten, M. Björnholm et al., “Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study,” Diabetes, vol. 54, no. 5, pp. 1459–1467, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Musi, M. F. Hirshman, J. Nygren et al., “Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes,” Diabetes, vol. 51, no. 7, pp. 2074–2081, 2002. View at Google Scholar · View at Scopus
  30. T. P. Ciaraldi, A. P. S. Kong, N. V. Chu et al., “Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects,” Diabetes, vol. 51, no. 1, pp. 30–36, 2002. View at Google Scholar · View at Scopus
  31. M. M. Meyer, K. Levin, T. Grimmsmann et al., “Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes,” Diabetes, vol. 51, no. 9, pp. 2691–2697, 2002. View at Google Scholar · View at Scopus
  32. Y. Miyazaki, H. He, L. J. Mandarino, and R. A. DeFronzo, “Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients,” Diabetes, vol. 52, no. 8, pp. 1943–1950, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. D. K. Coletta, A. Sriwijitkamol, E. Wajcberg et al., “Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial,” Diabetologia, vol. 52, no. 4, pp. 723–732, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Hammarstedt, C. X. Andersson, V. Rotter Sopasakis, and U. Smith, “The effect of PPARγ ligands on the adipose tissue in insulin resistance,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 1, pp. 65–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Hammarstedt, V. R. Sopasakis, S. Gogg, P.-A. Jansson, and U. Smith, “Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects,” Diabetologia, vol. 48, no. 1, pp. 96–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Jiang, Q. Dallas-Yang, S. Biswas, Z. Li, and B. B. Zhang, “Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPARγ), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo,” Biochemical Journal, vol. 377, no. 2, pp. 339–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. M. E. Griffin, M. J. Marcucci, G. W. Cline et al., “Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade,” Diabetes, vol. 48, no. 6, pp. 1270–1274, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Jiang, Q. Dallas-Yang, Z. Li et al., “Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR? agonists,” Diabetes, vol. 51, no. 8, pp. 2412–2419, 2002. View at Google Scholar · View at Scopus
  39. U. Smith, S. Gogg, A. Johansson, T. Olausson, V. Rotter, and B. Svalstedt, “Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes,” The FASEB Journal, vol. 15, no. 1, pp. 215–220, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Zhang, J. Berger, G. Zhou et al., “Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor ?,” Journal of Biological Chemistry, vol. 271, no. 50, pp. 31771–31774, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, “Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site,” Journal of Biological Chemistry, vol. 272, no. 8, pp. 5128–5132, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. H. S. Camp, S. R. Tafuri, and T. Leff, “c-jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-γ1 and negatively regulates its transcriptional activity,” Endocrinology, vol. 140, no. 1, pp. 392–397, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Shao, S. M. Rangwala, S. T. Bailey, S. L. Krakow, M. J. Reginato, and M. A. Lazar, “Interdomain communication regulating ligand binding by PPAR-γ,” Nature, vol. 396, no. 6709, pp. 377–380, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. H. S. Camp and S. R. Tafuri, “Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase,” Journal of Biological Chemistry, vol. 272, no. 16, pp. 10811–10816, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, “Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site,” Journal of Biological Chemistry, vol. 272, no. 8, pp. 5128–5132, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Han, D. P. Hajjar, J. M. Tauras, J. Feng, A. M. Gotto Jr., and A. C. Nicholson, “Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 1241–1246, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Rochette-Egly, “Nuclear receptors: integration of multiple signalling pathways through phosphorylation,” Cellular Signalling, vol. 15, no. 4, pp. 355–366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. E. Floyd and J. M. Stephens, “Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes,” Journal of Biological Chemistry, vol. 277, no. 6, pp. 4062–4068, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Ristow, D. Müller-Wieland, A. Pfeiffer, W. Krone, and C. R. Kahn, “Obesity associated with a mutation in a genetic regulator of adipocyte differentiation,” The New England Journal of Medicine, vol. 339, no. 14, pp. 953–959, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. S. M. Rangwala, B. Rhoades, J. S. Shapiro et al., “Genetic modulation of PPAR? phosphorylation regulates insulin sensitivity,” Developmental Cell, vol. 5, no. 4, pp. 657–663, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. Z. Wu, Y. Xie, R. F. Morrison, N. L. R. Bucher, and S. R. Farmer, “PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes,” Journal of Clinical Investigation, vol. 101, no. 1, pp. 22–32, 1998. View at Google Scholar · View at Scopus
  53. C. A. Baumann, N. Chokshi, A. R. Saltiel, and V. Ribon, “Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene,” Journal of Biological Chemistry, vol. 275, no. 13, pp. 9131–9135, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Rieusset, J. Auwerx, and H. Vidal, “Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 265, no. 1, pp. 265–271, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Furuta, Y. Yano, E. C. Gabazza et al., “Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 56, no. 3, pp. 159–171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Armoni, N. Kritz, C. Harel et al., “Peroxisome proliferator-activated receptor-? represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 30614–30623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. V. Ribon, J. H. Johnson, H. S. Camp, and A. R. Saltiel, “Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 25, pp. 14751–14756, 1998. View at Google Scholar · View at Scopus
  58. W. Liao, M. T. A. Nguyen, T. Yoshizaki et al., “Suppression of PPAR-? attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes,” American Journal of Physiology, vol. 293, no. 1, pp. E219–E227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. A. W. Norris, L. Chen, S. J. Fisher et al., “Muscle-specific PPAR?-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 608–618, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. A. L. Hevener, W. He, Y. Barak et al., “Muscle-specific Pparg deletion causes insulin resistance,” Nature Medicine, vol. 9, no. 12, pp. 1491–1497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Y. Kim, H. S. Cho, W. H. Jung, S. S. Kim, and H. G. Cheon, “Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-β signaling in adipocytes and myotubes,” Molecular Pharmacology, vol. 71, no. 6, pp. 1554–1562, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Luquet, J. Lopez-Soriano, D. Holst et al., “Peroxisome proliferator-activated receptor d controls muscle development and oxidative capability,” FASEB Journal, vol. 17, no. 15, pp. 2299–2301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor d activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. D. K. Krämer, L. Al-Khalili, S. Perrini et al., “Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor d,” Diabetes, vol. 54, no. 4, pp. 1157–1163, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Koutnikova, T.-A. Cock, M. Watanabe et al., “Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR? hypomorphic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 24, pp. 14457–14462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. W. He, Y. Barak, A. Hevener et al., “Adipose-specific peroxisome proliferator-activated receptor ? knockout causes insulin resistance in fat and liver but not in muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15712–15717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. J. R. Jones, C. Barrick, K.-A. Kim et al., “Deletion of PPAR? in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6207–6212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994. View at Google Scholar · View at Scopus
  70. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Tontonoz, E. Hu, J. Devine, E. G. Beale, and B. M. Spiegelman, “PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene,” Molecular and Cellular Biology, vol. 15, no. 1, pp. 351–357, 1995. View at Google Scholar · View at Scopus
  72. K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre et al., “PPARa and PPAR? activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” The EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996. View at Google Scholar · View at Scopus
  73. T. Imai, R. Takakuwa, S. Marchand et al., “Peroxisome proliferator-activated receptor ? is required in mature white and brown adipocytes for their survival in the mouse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4543–4547, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Gurnell, “Peroxisome proliferator-activated receptor γ and the regulation of adipocyte function: lesssons from human genetic studies,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 19, no. 4, pp. 501–523, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. Z. Wu, N. L. R. Bucher, and S. R. Farmer, “Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids,” Molecular and Cellular Biology, vol. 16, no. 8, pp. 4128–4136, 1996. View at Google Scholar · View at Scopus
  76. Z. Wu, Y. Xie, N. L. R. Bucher, and S. R. Farmer, “Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis,” Genes and Development, vol. 9, no. 19, pp. 2350–2363, 1995. View at Google Scholar · View at Scopus
  77. S. Perrini, L. Laviola, A. Cignarelli et al., “Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells,” Diabetologia, vol. 51, no. 1, pp. 155–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. J. B. Kim and B. M. Spiegelman, “ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism,” Genes and Development, vol. 10, no. 9, pp. 1096–1107, 1996. View at Google Scholar · View at Scopus
  79. L. Fajas, K. Schoonjans, L. Gelman et al., “Regulation of peroxisome proliferator-activated receptor ? expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism,” Molecular and Cellular Biology, vol. 19, no. 8, pp. 5495–5503, 1999. View at Google Scholar · View at Scopus
  80. Z. Wu, E. D. Rosen, R. Brun et al., “Cross-regulation of C/EBPa and PPAR? controls the transcriptional pathway of adipogenesis and insulin sensitivity,” Molecular Cell, vol. 3, no. 2, pp. 151–158, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Elbrecht, Y. Chen, C. A. Cullinan et al., “Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors ?1 and ?2,” Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 431–437, 1996. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. Gimble, C. E. Robinson, X. Wu et al., “Peroxisome proliferator-activated aeceptor-? activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells,” Molecular Pharmacology, vol. 50, no. 5, pp. 1087–1094, 1996. View at Google Scholar · View at Scopus
  83. F. M. Torti, B. Dieckmann, and B. Beutler, “A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia,” Science, vol. 229, no. 4716, pp. 867–869, 1985. View at Google Scholar · View at Scopus
  84. J. M. Stephens and P. H. Pekala, “Transcriptional repression of the C/EBP-α and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-α. Regulation is coordinate and independent of protein synthesis,” Journal of Biological Chemistry, vol. 267, no. 19, pp. 13580–13584, 1992. View at Google Scholar · View at Scopus
  85. D. Szalkowski, S. White-Carrington, J. Berger, and B. Zhang, “Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells,” Endocrinology, vol. 136, no. 4, pp. 1474–1481, 1995. View at Google Scholar · View at Scopus
  86. B. Zhang, J. Berger, E. Hu et al., “Negative regulation of peroxisome proliferator-activated receptor-? gene expression contributes to the antiadipogenic effects of tumor necrosis factor-a,” Molecular Endocrinology, vol. 10, no. 11, pp. 1457–1466, 1996. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Ron, A. R. Brasier, R. E. McGehee Jr., and J. F. Habener, “Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP),” Journal of Clinical Investigation, vol. 89, no. 1, pp. 223–233, 1992. View at Google Scholar · View at Scopus
  88. C. B. Kallen and M. A. Lazar, “Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 5793–5796, 1996. View at Publisher · View at Google Scholar · View at Scopus
  89. A. N. Hollenberg, V. S. Susulic, J. P. Madura et al., “Functional antagonism between CCAAT/enhancer binding protein-a and peroxisome proliferator-activated receptor-? on the leptin promoter,” Journal of Biological Chemistry, vol. 272, no. 8, pp. 5283–5290, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Okuno, H. Tamemoto, K. Tobe et al., “Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1354–1361, 1998. View at Google Scholar · View at Scopus
  91. E. Hu, P. Liang, and B. M. Spiegelman, “AdipoQ is a novel adipose-specific gene dysregulated in obesity,” Journal of Biological Chemistry, vol. 271, no. 18, pp. 10697–10703, 1996. View at Publisher · View at Google Scholar · View at Scopus
  92. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends in Endocrinology and Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. J. G. Yu, S. Javorschi, A. L. Hevener et al., “The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects,” Diabetes, vol. 51, no. 10, pp. 2968–2974, 2002. View at Google Scholar · View at Scopus
  94. U. B. Pajvani, M. Hawkins, T. P. Combs et al., “Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12152–12162, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Yamauchi, J. Kamon, Y. Minokoshi et al., “Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase,” Nature Medicine, vol. 8, no. 11, pp. 1288–1295, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. A. R. Nawrocki, M. W. Rajala, E. Tomas et al., “Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor ? agonists,” Journal of Biological Chemistry, vol. 281, no. 5, pp. 2654–2660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. R. R. Banerjee, S. M. Rangwala, J. S. Shapiro et al., “Regulation of fasted blood glucose by resistin,” Science, vol. 303, no. 5661, pp. 1195–1198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. K. T. Uysal, S. M. Wiesbrock, M. W. Marino, and G. S. Hotamisligil, “Protection from obesity-induced insulin resistance in mice lacking TNF-α function,” Nature, vol. 389, no. 6651, pp. 610–614, 1997. View at Publisher · View at Google Scholar · View at Scopus
  100. U. Kintscher and R. E. Law, “PPARγ-mediated insulin sensitization: the importance of fat versus muscle,” American Journal of Physiology, vol. 288, no. 2, pp. E287–E291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. O. Gavrilova, M. Haluzik, K. Matsusue et al., “Liver peroxisome proliferator-activated receptor ? contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass,” Journal of Biological Chemistry, vol. 278, no. 36, pp. 34268–34276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Yu, K. Matsusue, P. Kashireddy et al., “Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor ?1 (PPAR?1) overexpression,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Promrat, G. Lutchman, G. I. Uwaifo et al., “A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis,” Hepatology, vol. 39, no. 1, pp. 188–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. V. Ratziu, P. Giral, S. Jacqueminet et al., “Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial,” Gastroenterology, vol. 135, no. 1, pp. 100–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. H. Bays, L. Mandarino, and R. A. DeFronzo, “Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 463–478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre et al., “PPARa and PPAR? activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” The EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996. View at Google Scholar · View at Scopus
  109. B. I. Frohnert, T. Y. Hui, and D. A. Bernlohr, “Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene,” Journal of Biological Chemistry, vol. 274, no. 7, pp. 3970–3977, 1999. View at Publisher · View at Google Scholar · View at Scopus
  110. H.-P. Guan, L. Yong, M. V. Jensen, C. B. Newgard, C. M. Steppan, and M. A. Lazar, “A futile metabolic cycle activated in adipocytes by antidiabetic agents,” Nature Medicine, vol. 8, no. 10, pp. 1122–1128, 2002. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Tordjman, G. Chauvet, J. Quette, E. G. Beale, C. Forest, and B. Antoine, “Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells,” Journal of Biological Chemistry, vol. 278, no. 21, pp. 18785–18790, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. J. B. Buse, M. H. Tan, M. J. Prince, and P. P. Erickson, “The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 6, no. 2, pp. 133–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo, “Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4312–4319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Matsui, Y. Terauchi, N. Kubota et al., “Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-?-deficient mice on a high-fat diet,” Diabetes, vol. 53, no. 11, pp. 2844–2854, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler, “Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3-kinase-dependent pathway,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6678–6686, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. F. Lalloyer, B. Vandewalle, F. Percevault et al., “Peroxisome proliferator-activated receptor a improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets,” Diabetes, vol. 55, no. 6, pp. 1605–1613, 2006. View at Publisher · View at Google Scholar · View at Scopus